linjc16/ctgov huggingface dataset:
Effects of Caffeine on Methacholine Challenge and Exhaled Nitric Oxide Levels.

Study Overview
=================
Brief Summary
-----------------
To investigate whether or not the ingestion of caffeine with alter airway responsiveness to methacholine and/or change the level of exhaled nitric oxide.

Official Title
-----------------
The Effects of Caffeine on Exhaled Nitric Oxide Levels and Methacholine PC20

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Other: caffeine
* Other: No caffeine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of asthma FEV1 greater than 65% Exclusion Criteria: asthma is poorly controlled presence of other airway disease (e.g. COPD)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: coffee with caffeine<br> | Other: caffeine<br>* Starbuck's Grande Pike Roast coffee<br>|
| Placebo Comparator: decaffeinated coffee<br>Starbuck's Grande Pike Roast Decaf | Other: No caffeine<br>* Starbuck's Grande Pike Roast Decaffeinated Coffee<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| methacholine pc20 |  | 1 hour post ingestion |
Study to Evaluate Cardiac Hemodynamics and Safety of SLV320 in Subjects With Congestive Heart Failure

Study Overview
=================
Brief Summary
-----------------
The study is a randomized, placebo controlled, multi-center, single dose study to evaluate cardiac hemodynamics and safety of iv SLV320 in 110 subjects with congestive heart failure requiring diuretic treatment. Each subject will receive one dose of SLV320 or placebo or furosemide. The study consists of three visits (or study days when in-subjects are included). Ambulatory subjects will be in hospital for two nights and one day.

Official Title
-----------------
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Parallel Group, Single Dose Study to Evaluate Cardiac Hemodynamics and Safety During Right Heart Catheterization of Three IV Doses of SLV320 in Subjects With Congestive Heart Failure Requiring Diuretic Treatment

Conditions
-----------------
Congestive Heart Failure

Intervention / Treatment
-----------------
* Drug: SLV320


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: history of chronic, symptomatic, mild to severe (NYHA Class II-IV) CHF for at least three months requiring treatment with diuretics and with documented systolic dysfunction on stable doses of their individually optimized medication regimen for at least one week prior to enrollment Exclusion Criteria: required hospitalization (for cardiovascular disease) or adjustment of background medications for CHF orthostatic hypotension or symptomatic orthostasis sitting systolic or diastolic blood pressure < 90 mmHg 2nd or 3rd degree atrio-ventricular block or sick sinus syndrome heart rate of < 50 or > 110 bpm on the ECG transplanted heart heart failure due to primary valvular disease (unless surgically corrected), obstructive cardiomyopathy, pericardial disease, cor pulmonale or congenital heart disease hemodynamically significant left ventricular outflow tract obstruction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: SLV320|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
congestive heart failure, adenosine receptor blocker, cardiac hemodynamic
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma

Study Overview
=================
Brief Summary
-----------------
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors. In addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung metastasis through this study.

Official Title
-----------------
The Efficacy of New Adjuvant Chemotherapy of Osteosarcoma Combined With Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma

Conditions
-----------------
Lung Metastases, Tumor Necrosis

Intervention / Treatment
-----------------
* Drug: Zoledronic Acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with osteosarcoma who were diagnosed with initial pathology and pathology were excluded from lung metastasis or other metastatic lesions by CT and total body emission-computed tomography, and patients with standard chemotherapy were evaluated. Exclusion Criteria: Pulmonary metastasis, pregnancy or lactation, renal insufficiency (creatinine clearance <70 ml/min/1.73 m2), liver dysfunction, obvious oral disease, and unsuitable for bisphosphonate treatment after evaluation, have been found. With diseases that still require hormone therapy, abnormal blood system, heart disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: experimental group<br> | Drug: Zoledronic Acid<br> <br> |
| No Intervention: control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of lung metastasis | Discovery the rate of neonatal lung metastases by high-resolution chest CT | 3 year | 
| rate of tumor recurrence | Local recurrence rate of tumor or rate of distant metastasis | 3 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of tumor necrosis less than 90% | the rate of patients that postoperative tumor necrosis rate was estimated to be lower than grade III（90%） | 3 year |
Behavioural Treatment of Hypertension

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to determine whether psychological therapy (self-help or individualized intense stress management) is different than a single drug treatment in terms of their effectiveness for lowering blood pressure.

Official Title
-----------------
Behavioural Treatment of Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Hydrochlorothiazide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: must be at least 19 years of age subjects can be male or female subjects must have an average resting blood pressure of >140 systolic pressure an/ or >90 diastolic pressure off anti-hypertensive medication Exclusion Criteria: must not be on more than 2 blood pressure lowering drugs must not have known or suspected of having secondary hypertension on initial examination must not be pregnant or anticipating pregnancy during study period must not have history of allergy, hypersensitivity or intolerance to diuretics must not have medical condition that may result in an unacceptable risk of complications due to uncontrolled hypertension during time period of study must not have average resting BP readings that exceed 190 systolic, or 115 diastolic, or have two consecutive readings of 180 systolic or 110 diastolic

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Hydrochlorothiazide|Not recorded in detailed description.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Day time ambulatory BP |  | See description | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 24 hour ambulatory BP, and office resting BP |  | See description | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, ambulatory BP, office resting BP, hydrochlorothiazide, stress reduction, self-help, psychotherapy, efficacy
Nurse-led Pain Education Clinical Trial in Chronic Pain Patients

Study Overview
=================
Brief Summary
-----------------
Chronic pain is a multidimensional problem that consequently requires interventions on multiple levels. Pain education by physicians is one of the interventions that shows promising results in patient reported outcomes. It is however unclear if nurse-led chronic pain education could be equally effective on pain attitude and behavior in chronic pain patients. The aim of this clinical trial is to investigate the effects of a nurse-led consultation with chronic pain patients on pain attitude and patient satisfaction compared with regular care without nurse specialist intervention.

Official Title
-----------------
Effect Van Preklinische Nurse-led Neuroscience Pijneducatie op de Attituden Ten Opzichte Van Chronische Pijn en de patiënttevredenheid in Een Universitair Pijncentrum: Een Monocentrische RCT

Conditions
-----------------
Pain, Chronic

Intervention / Treatment
-----------------
* Behavioral: Nurse-led care by a nurse specialist in pain


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old dutch speaking first time consultation Exclusion Criteria: Palliative care patients Patients with dementia diagnosis Urgent referral to the pain clinic by other physicians

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Standard physician led care<br>Consultation by physician (pain specialist) | |
| Experimental: Nurse-led care<br>Preclinical nurse-led consultation and standard care by physician (pain specialist) | Behavioral: Nurse-led care by a nurse specialist in pain<br>* A nurse pain specialist consultation in patients in the experimental arm before they receive standard care by a physician.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient attitude on chronic pain | Pain Solutions Questionnaire (PaSol) | Up to 10 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction | Core questionnaire for the assessment of patient satisfaction in academic hospitals (COPS) | Up to 10 months |
Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan

Study Overview
=================
Brief Summary
-----------------
Written informed consent must be obtained before any study specific procedures are undertaken. The process of the experiment (brief describe) The patients must come back for follow during 4 to 12 weeks after starting the new therapy. The investigators will follow the patients' lipid profile and any side effects and stop the observation till 36 months after starting the new therapy. The serum level of HIV-VL, CD4, GOT, GPT, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol will be checked every 3 months. The patients' chart and all data will be delinked to protect the patients' right and privacy.

Official Title
-----------------
Tropical Medicine Center (TMC), Kaohsiung Medicine University Hospital (KMUH)

Conditions
-----------------
HIV

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV-infected patients who receive HAART therapy but have metabolic side effects. Age over 20 years old Exclusion Criteria: Abnormal liver function: GOT or GPT 5 times over normal upper limit
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation

Study Overview
=================
Brief Summary
-----------------
The hypothesis being tested is that in patients with stable claudication and documented PAD, omega-3 supplementation for 1 month will lead to improvement in endothelial function as measured by flow-mediated, brachial artery vasodilation (FMD), as well as improvement in the vascular inflammatory profile as measured by a panel of established circulating inflammatory biomarkers.

Official Title
-----------------
The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation

Conditions
-----------------
Peripheral Arterial Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Pro-Omega
* Dietary Supplement: Omega 3 Fatty Acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: intermittent claudication resting or exercise Ankle-Brachial Index (ABI) <0.9 age 50 and more Exclusion Criteria: critical limb ischemia hypersensitivity/allergies to fish or seafood already on omega-3 fatty acids or equivalent significant renal, hepatic, and inflammatory disease concurrent severe infections acute illness (MI, stroke, major surgery within 30 days) receiving immunosuppressive medications or steroids

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pro-Omega<br>High-dose, short-duration dietary omega-3 fatty acids supplementation | Dietary Supplement: Pro-Omega<br>* Pro-Omega, 4.4gm/day x 1 month<br>Dietary Supplement: Omega 3 Fatty Acid<br>* 4.4 gm/day for 1 month<br>|
| Placebo Comparator: Placebo<br> | Dietary Supplement: Pro-Omega<br>* Pro-Omega, 4.4gm/day x 1 month<br>Dietary Supplement: Omega 3 Fatty Acid<br>* 4.4 gm/day for 1 month<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial Function | Flow-mediated, brachial artery vasodilation (FMD) | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory bio-markers | Inflammatory bio-markers: C-reactive protein (hsCRP), interleukin-6 (IL-6), soluble intracellular adhesion molecule-1 (sICAM-1) and the anti-inflammatory mediator 15-epimeric lipoxin | 1 month |
Early Lung Rehabilitation Care for Patients After Double Lung Transplantation

Study Overview
=================
Brief Summary
-----------------
Develop appropriate individual programs for patients to implement lung rehabilitation safely and effectively.

Detailed Description
-----------------
Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.

Official Title
-----------------
Early Lung Rehabilitation Care for Patients After Double Lung Transplantation

Conditions
-----------------
Pulmonary Disease

Intervention / Treatment
-----------------
* Behavioral: Individualized lung rehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients after double lung transplantation; informed consent Exclusion Criteria: unstable condition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Interventional Model Description: experience summary
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Individualized lung rehabilitation programme<br>Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support. | Behavioral: Individualized lung rehabilitation<br>* Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU hospital stay | the stay time spent in ICU | 1 year |
Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia

Study Overview
=================
Brief Summary
-----------------
Anaemia is a common consequence of chronic renal failure. Darbepoetin alfa is a unique erythropoietic protein that stimulates erythropoiesis by the same mechanism as endogenous erythropietin and conventional recombinant human erythropoietin (rHuEPO). Darbepoetin alfa has been shown to have a serum half-life 3-fold longer than that of rHuEPO, which allows dosing at extended intervals and less frequent injection. The objective is to evaluate the efficacy and safety of darbepoetin alfa therapy given at an extended once monthly dosing interval in the treatment of renal anaemia in continuous ambulatory peritoneal dialysis.

Official Title
-----------------
Conversion From Once Weekly Recombinant Human Erythropoietin to Once Monthly Darbepoetin Alfa for the Treatment of Renal Anemia in Continuous Ambulatory Peritoneal Dialysis Patients

Conditions
-----------------
Anemia, Kidney Failure, Chronic, Peritoneal Dialysis, Continuous Ambulatory

Intervention / Treatment
-----------------
* Drug: Darbepoetin alfa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients on continuous ambulatory peritoneal dialysis Patients receiving subcutaneous recombinant human erythropoietin (rHuEPO) Patients with haemoglobin level ?10 g/dL and remain stable for the past 3 months while receiving rHuEPO Exclusion Criteria: Uncontrolled hypertension Severe congestive heart failure (NYHA class III or IV) Grand mal epilepsy Any kind of blood loss causing Fe depletion Presence of infection, either acute or chronic, or inflammatory conditions within 3 months preceding the study Malignancy Aluminum toxicity Severe hyperparathyroidism with marrow fibrosis or osteitis fibrosa _ PTH > 20 times of normal Vitamin B12 or folate deficiency _ MCV > 100fL Haemolysis Marrow dysfunction e.g. aplastic anaemia, myelodysplastic syndrome, multiple myeloma, etc Thalassaemia major, intermediate or minor, or red cell enzyme defects Blood transfusion within 3 months preceding the study Pregnancy or lactating mothers
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Darbepoetin alfa|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemoglobin level |  | Over 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anemia, End-stage renal failure, Continuous ambulatory peritoneal dialysis